共查询到2条相似文献,搜索用时 15 毫秒
1.
O. Sahota I. Fowler P. J. Blackwell N. Lawson S. A. Cawte P. San T. Masud D. J. Hosking 《Osteoporosis international》2000,11(11):959-966
A number of drugs are now available for the treatment of established osteoporosis and have been shown to significantly increase
bone mineral density (BMD). There are, however, few comparative treatment studies and, furthermore, adverse events remain
a problem with some of the newer agents, particularly in the elderly, in everyday clinical practice. We report a 12 month,
open labeled, randomized controlled, prospective treatment study in 140 postmenopausal women with established vertebral osteoporosis,
comparing the effect of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in terms of gain
in BMD, reduction in bone turnover markers and adverse event profile. The mean percentage increases in BMD at 12 months, at
the spine and hip respectively, were: continuous alendronate 5.7%, 2.6%; cyclical alendronate 4.1%, 1.6%; cyclical etidronate
4.9%, 2.0% (p<0.01) and calcitriol 2.0%, 0.4% (NS). In comparison with calcitriol, the mean changes in BMD at the spine and hip respectively
were greater in the other groups; continuous alendronate: 3.7% (95% CI 1.4 to 8.3), 2.2% (95% CI 0.7 to 4.0); cyclical alendronate:
2.1% (95% CI 1.2 to 6.4), 1.2% (95% CI −0.3 to 3.0); cyclical etidronate: 2.9% (95% CI 1.9 to 6.5), 1.6% (95% CI 0.9 to 3.1)).
The reduction in bone turnover markers was between 26% and 32% in the alendronate and etidronate groups (p<0.01), with a trend toward greater reduction in the continuous alendronate group. Eight patients discontinued the study:
6 in the continuous alendronate group, 1 in the cyclical alendronate group and 1 in the calcitriol group. Two patients in
the cyclical etidronate group were unable to tolerate the Cacit component, but continued on substituting Cacit with Calcichew.
In summary, 12 months of treatment with continuous alendronate, cyclical alendronate and cyclical etidronate are effective
in terms of the gain in BMD at the anteroposterior spine and total hip in a comparable treatment population. These treatments
are more effective than calcitriol and were generally well tolerated. Continuous alendronate showed a trend toward a larger
gain in BMD and greater suppression of bone turnover markers than the other treatment groups, but had a higher incidence of
adverse events, particularly within the older subgroup. Cyclical alendronate offers a lower adverse event profile and appears
to be effective in comparison with continuous treatment, and may possibly be an alternative in the elderly. However, further
studies are necessary, but more importantly with fracture end-points.
Received: 6 April 1999 / Accepted: 8 June 2000 相似文献
2.
D. H. Gutteridge D. H. Gutteridge G. O. Stewart R. L. Prince R. L. Prince R. I. Price R. W. Retallack S. S. Dhaliwal B. G. A. Stuckey P. Drury C. E. Jones D. L. Faulkner G. N. Kent C. I. Bhagat G. C. Nicholson G. C. Nicholson K. Jamrozik? 《Osteoporosis international》2002,13(2):158-170
Postmenopausal Caucasian women aged less than 80 years (n= 99) with one or more atraumatic vertebral fracture and no hip fractures, were treated by cyclical administration of enteric coated sodium fluoride (NaF) or no NaF for 27 months, with precautions to prevent excessive stimulation of bone turnover. In the
first study 65 women, unexposed to estrogen (–E study), age 70.8 ± 0.8 years (mean ± SEM) were all treated with calcium (Ca)
1.0–1.2 g daily and ergocalciferol (D) 0.25 mg per 25 kg once weekly and were randomly assigned to cyclical NaF (6 months
on, 3 months off, initial dose 60 mg/day; group F CaD, n= 34) or no NaF (group CaD, n= 31). In the second study 34 patients, age 65.5 ± 1.2 years, on hormone replacement therapy (E) at baseline, had this standardized,
and were all treated with Ca and D and similarly randomized (FE CaD, n= 17; E CaD, n= 17) (+E study). The patients were stratified according to E status and subsequently assigned randomly to ± NaF. Seventy-five
patients completed the trial. Both groups treated with NaF showed an increase in lumbar spinal density (by DXA) above baseline
by 27 months: FE CaD + 16.2% and F CaD +9.3% (both p= 0.0001). In neither group CaD nor E CaD did lumbar spinal density increase. Peripheral bone loss occurred at most sites
in the F CaD group at 27 months: tibia/fibula shaft –7.3% (p= 0.005); femoral shaft –7.1% (p= 0.004); distal forearm –4.0% (p = 0.004); total hip –4.1% (p = 0.003); and femoral neck –3.5% (p= 0.006). No significant loss occurred in group FE CaD. Differences between the two NaF groups were greatest at the total
hip at 27 months but were not significant [p<0.05; in view of the multiple bone mineral density (BMD) sites, an alpha of 0.01 was employed to denote significance in BMD
changes throughout this paper]. Using Cox’s proportional hazards model, in the –E study there were significantly more patients
with first fresh vertebral fractures in those treated with NaF than in those not so treated (RR = 24.2, p= 0.008, 95% CI 2.3–255). Patients developing first fresh fractures in the first 9 months were markedly different between
groups: –23% of F CaD, 0 of CaD, 29% of FE CaD and 0 of E CaD. The incidence of incomplete (stress) fractures was similar
in the two NaF-treated groups. Complete nonvertebral fractures did not occur in the two +E groups; there were no differences
between groups F CaD and CaD. Baseline BMD (spine and femoral neck) was related to incident vertebral fractures in the control
groups (no NaF), but not in the two NaF groups. Our results and a literature review indicate that fluoride salts, if used,
should be at low dosage, with pretreatment and co-treatment with a bone resorption inhibitor.
Received: 22 August 2000 / Accepted: 23 July 2001 相似文献